181 related articles for article (PubMed ID: 14565594)
1. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study.
Gonnelli S; Cepollaro C; Montagnani A; Bruni D; Caffarelli C; Breschi M; Gennari L; Gennari C; Nuti R
Calcif Tissue Int; 2003 Aug; 73(2):133-9. PubMed ID: 14565594
[TBL] [Abstract][Full Text] [Related]
2. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study.
Gonnelli S; Cepollaro C; Montagnani A; Martini S; Gennari L; Mangeri M; Gennari C
Osteoporos Int; 2002 May; 13(5):415-21. PubMed ID: 12086353
[TBL] [Abstract][Full Text] [Related]
3. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
[TBL] [Abstract][Full Text] [Related]
4. Unique and common genetic effects between bone mineral density and calcaneal quantitative ultrasound measures: the Fels Longitudinal Study.
Lee M; Czerwinski SA; Choh AC; Demerath EW; Sun SS; Chumlea WC; Towne B; Siervogel RM
Osteoporos Int; 2006; 17(6):865-71. PubMed ID: 16541205
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population.
Haugeberg G; Ørstavik RE; Uhlig T; Falch JA; Halse JI; Kvien TK
Osteoporos Int; 2003 Jun; 14(4):312-9. PubMed ID: 12730749
[TBL] [Abstract][Full Text] [Related]
6. Calcaneal ultrasonometry: response to treatment in comparison with dual x-ray absorptiometry measurements of the lumbar spine and femur.
Rosenthall L; Caminis J; Tenehouse A
Calcif Tissue Int; 1999 Mar; 64(3):200-4. PubMed ID: 10024375
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the longitudinal changes in quantitative ultrasound with dual-energy X-ray absorptiometry: the four-year effects of hormone replacement therapy.
Sahota O; San P; Cawte SA; Pearson D; Hosking DJ
Osteoporos Int; 2000; 11(1):52-8. PubMed ID: 10663359
[TBL] [Abstract][Full Text] [Related]
8. Does the combination of quantitative ultrasound and dual-energy X-ray absorptiometry improve fracture discrimination?
Frost ML; Blake GM; Fogelman I
Osteoporos Int; 2001; 12(6):471-7. PubMed ID: 11446563
[TBL] [Abstract][Full Text] [Related]
9. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
10. [X-ray densitometry and ultrasonography of the heel bone--sensitivity and comparison with densitometry of the axial skeleton].
Michalská D; Zikán V; Stĕpán J; Weichetová M; Kubová V; Krenková J; Masatová A
Cas Lek Cesk; 2000 Apr; 139(8):231-6. PubMed ID: 10916211
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bone mineral density with dual energy x-ray absorptiometry, quantitative ultrasound and single energy x-ray absorptiometry.
El-Desouki MI; Sherafzal MS; Othman SA
Saudi Med J; 2005 Sep; 26(9):1346-50. PubMed ID: 16155646
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.
Gonnelli S; Martini G; Caffarelli C; Salvadori S; Cadirni A; Montagnani A; Nuti R
Osteoporos Int; 2006 Oct; 17(10):1524-31. PubMed ID: 16767526
[TBL] [Abstract][Full Text] [Related]
14. Changes in QUS and BMD measurements with antiresorptive therapy: a two-year longitudinal study.
Frost ML; Blake GM; Fogelman
Calcif Tissue Int; 2001 Sep; 69(3):138-46. PubMed ID: 11683528
[TBL] [Abstract][Full Text] [Related]
15. Leisure physical activity is associated with quantitative ultrasound measurements independently of bone mineral density in postmenopausal women.
Blanchet C; Giguère Y; Prud'homme D; Turcot-Lemay L; Dumont M; Leduc G; Côte S; Laflamme N; Rousseau F; Dodin S
Calcif Tissue Int; 2003 Oct; 73(4):339-49. PubMed ID: 12874703
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Ultrasound and Dual X-Ray Absorptiometry as Indicators of Bone Mineral Density in Young Women and Nutritional Factors Affecting It.
Schraders K; Zatta G; Kruger M; Coad J; Weber J; Brough L; Thomson J
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31581575
[TBL] [Abstract][Full Text] [Related]
17. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
[TBL] [Abstract][Full Text] [Related]
19. Contact quantitative ultrasound: an evaluation of precision, fracture discrimination, age-related bone loss and applicability of the WHO criteria.
Frost ML; Blake GM; Fogelman I
Osteoporos Int; 1999; 10(6):441-9. PubMed ID: 10663343
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate on bone mineral density in male idiopathic osteoporosis.
Weber TJ; Drezner MK
Metabolism; 2001 Aug; 50(8):912-5. PubMed ID: 11474478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
